Cargando…

Time to Failure on Oral Glucose-Lowering Agents for Patients with Type 2 Diabetes: A Retrospective Cohort Study

INTRODUCTION: Research has shown that glycemic control is associated with lower rates of microvascular and long-term cardiovascular complications. In the analyses reported here, we examined treatment failure on oral glucose-lowering agents (GLAs), defined as having sustained hemoglobin A1c (HbA1c) ≥...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boye, Kristina S., Lage, Maureen J., Kiljański, Jacek
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099964/ https://www.ncbi.nlm.nih.gov/pubmed/33837921 http://dx.doi.org/10.1007/s13300-021-01051-9

Ejemplares similares

Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes
por: Perez-Nieves, Magaly, et al.
Publicado: (2018)

Chronic Medication Burden and Complexity for US Patients with Type 2 Diabetes Treated with Glucose-Lowering Agents
por: Boye, Kristina S., et al.
Publicado: (2020)

The Association Between HbA1c and 1-Year Diabetes-Related Medical Costs: A Retrospective Claims Database Analysis
por: Boye, Kristina S., et al.
Publicado: (2022)

Evaluating glucose‐lowering treatment in older people with diabetes: Lessons from the IMPERIUM trial
por: Sinclair, Alan J., et al.
Publicado: (2020)

The Association Between Sustained HbA1c Control and Long-Term Complications Among Individuals with Type 2 Diabetes: A Retrospective Study
por: Boye, Kristina S., et al.
Publicado: (2022)

Use of Glucose-Lowering Agents in Diabetes and CKD
por: Alicic, Radica Z., et al.
Publicado: (2022)

Reduced Glucose Variability With Glucose-Dependent Versus Glucose-Independent Therapies Despite Similar Glucose Control and Hypoglycemia Rates in a Randomized, Controlled Study of Older Patients With Type 2 Diabetes Mellitus
por: Pratley, Richard E., et al.
Publicado: (2018)

The Association Between Obesity and the 5-Year Prevalence of Morbidity and Mortality Among Adults with Type 2 Diabetes
por: Boye, Kristina S., et al.
Publicado: (2023)

Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population
por: Boye, Kristina S., et al.
Publicado: (2018)

Trends in HbA1c and Body Mass Index Among Individuals with Type 2 Diabetes: Evidence from a US Database 2012–2019
por: Boye, Kristina S., et al.
Publicado: (2021)

Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database
por: Boye, Kristina Secnik, et al.
Publicado: (2016)

Diabetes, bone and glucose-lowering agents: basic biology
por: Lecka-Czernik, Beata
Publicado: (2017)

Effects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites
por: Wang, Dongmei, et al.
Publicado: (2022)

The use of oral glucose-lowering agents (GLAs) in β-thalassemia patients with diabetes: Preliminary data from a retrospective study of ICET-A Network
por: de Sanctis, Vincenzo, et al.
Publicado: (2022)

Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes
por: Oshige, Tamami, et al.
Publicado: (2019)

Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self‐titrating insulin glargine U‐100
por: Hollander, Priscilla A., et al.
Publicado: (2019)

Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents
por: Infante, Marco, et al.
Publicado: (2022)

Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review
por: Hirose, Takahisa, et al.
Publicado: (2019)

Sodium-glucose Cotransporter-2 Inhibitors in Combination with Other Glucose-lowering Agents for the Treatment of Type 2 Diabetes Mellitus
por: Kalra, Sanjay, et al.
Publicado: (2018)

The association between diabetes related medical costs and glycemic control: A retrospective analysis
por: Oglesby, Alan K, et al.
Publicado: (2006)

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
por: Scheen, André J.
Publicado: (2018)

Effects of glucose-lowering agents on cardiorespiratory fitness
por: Hamasaki, Hidetaka
Publicado: (2018)

Effects of glucose-lowering agents on ischemic stroke
por: Avgerinos, Konstantinos, et al.
Publicado: (2017)

Associations between Oral Glucose-Lowering Agents and Increased Risk for Life-Threatening Arrhythmias in Patients with Type 2 Diabetes Mellitus—A Literature Review
por: Tudoran, Cristina, et al.
Publicado: (2023)

The dawn phenomenon in type 2 diabetes: its association with glucose excursions and changes after oral glucose-lowering drugs
por: Wang, Jun-Sing, et al.
Publicado: (2021)

The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus
por: Lv, You, et al.
Publicado: (2018)

The Effects of Glucose Lowering Agents on the Secondary Prevention of Coronary Artery Disease in Patients with Type 2 Diabetes
por: Jung, Inha, et al.
Publicado: (2021)

From glucose lowering agents to disease/diabetes modifying drugs: a “SIMPLE” approach for the treatment of type 2 diabetes
por: Mosenzon, Ofri, et al.
Publicado: (2021)

Glucose-lowering effects of orally administered superoxide dismutase in type 2 diabetic model rats
por: Guo, Jingke, et al.
Publicado: (2022)

The impact of Ramadan fasting on glucose variability in type 2 diabetes mellitus patients on oral anti diabetic agents
por: Harbuwono, Dante S., et al.
Publicado: (2020)

Impact of Glucose-Lowering Agents on the Risk of Cancer in Type 2 Diabetic Patients. The Barcelona Case-Control Study
por: Simó, Rafael, et al.
Publicado: (2013)

Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents
por: Tanaka, Atsushi, et al.
Publicado: (2021)

DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure
por: Kaplinsky, Edgardo
Publicado: (2020)

Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study
por: Vlacho, Bogdan, et al.
Publicado: (2021)

The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus
por: Lexis, Chris PH, et al.
Publicado: (2009)

Insulin Monotherapy Versus Insulin Combined with Other Glucose-Lowering Agents in Type 2 Diabetes: A Narrative Review
por: Abdi, Hengameh, et al.
Publicado: (2018)

Successful glucose lowering therapy triumphs in heart failure
por: Rossing, Peter
Publicado: (2021)

Influence of Supervised Disease Understanding and Diabetes Self-Management on Adherence to Oral Glucose-Lowering Treatment in Patients with Type 2 Diabetes
por: Doupis, John, et al.
Publicado: (2019)

Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States
por: Boye, Kristina S., et al.
Publicado: (2019)

Metformin Use Is Associated With a Lower Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus: a Retrospective Cohort Analysis
por: Tseng, Chin‐Hsiao
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_sbl2aahm7q9mbtmpr4qmd173ac